WASHINGTON (May 15, 2015) – PhRMA President and Chief Executive Officer John J. Castellani announced today that Executive Vice President, Administration, and Chief Financial Officer Del Persinger will retire effective May 31, concluding 18-1/2 years leading the organization’s finance and operations functions. Paul A. Aines, currently Chief Financial Officer and Senior Director of the American Society of Clinical Oncology (ASCO), will succeed Persinger. Aines will start at PhRMA on June 15.
“On behalf of our member companies and our entire staff, I want to thank Del for his steady management of PhRMA’s budgeting and finance, IT, human resources and administrative activities,” Castellani said. “It is a complex portfolio and Del managed it to the highest standard for nearly two decades. We benefit, our members benefit, and, ultimately, patients benefit when our organization is run as efficiently and effectively as Del helped us to do.”
Persinger joined PhRMA in 1996 after 21 years at the American Petroleum Institute. He started his career as a refinery process engineer at Exxon Company.
“It has been a privilege to work for America’s patients for so many years,” Persinger said. “Those patients are living longer, healthier lives because of PhRMA member companies’ dedication, investment and hard work. I know that trend will only continue, and my family and I look forward to watching it unfold.”
Capping off a succession of leadership roles, Aines has served as ASCO Chief Financial Officer and Senior Director, Finance and Administration, since January 2001. Previously, he served as Director, Finance and Computer Services for the Society of the Plastics Industry. A recipient of a B.S. in Accounting from Virginia Tech and an M.B.A. from The George Washington University, Aines started his career on the audit staff at professional services company KPMG LLP.
“In order to keep up with accelerating and evolving science, we need to be more rigorous than ever,” Castellani added. “Paul’s broad financial expertise and deep understanding of PhRMA’s critical stakeholders will help us grow as an organization and meet this great challenge.”
“I have cherished my time working for ASCO and helping them to advance their mission of improving cancer care throughout the world,” Aines said. “I am fortunate now to be afforded the opportunity to support a broader and equally laudable mission.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.
Connect with PhRMA
For information on how innovative medicines save lives, please visit: